Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.

Jim Miller

Articles

CDMOs can claim credit for the robust growth of emerging bio/pharma financings.

The industry will see an impact from financing, M&As, advanced therapies, generic drugs, and the retail market in 2018.

Recent acquisitions are creating CDMOs with scale that rivals global bio/pharma.

Mergers and acquisitions are positive for the CDMO industry, but there is a downside.